Kaplan Fox Encourages Erasca, Inc. (ERAS) Investors with Losses to Contact the Firm Before August 10, 2026

Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS) on behalf of investors that purchased or otherwise acquired Erasca securities between January 14, 2025 and April 26, 2026 (the "Class Period"). If you are an investor in Erasca and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than August 10, 2026 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.

According to the complaint, on April 27, 2026, before the market opened, Erasca disclosed in a Form 8-K that it had received a letter from legal counsel for Revolution Medicines, Inc. ("RevMed") alleging that Erasca's ERAS-0015 infringes a RevMed patent and is connected to alleged trade secret misappropriation. Further, according to the complaint, RevMed also alleged that Erasca had "improperly compared preclinical data of ERAS-0015 and RMC-6236 in public disclosures" and demanded Erasca cease making "deceptive and untrue comparative statements comparing ERAS-0015 and RMC-6236." The Company has stated that it believes the assertions are without merit and intends to contest the allegations.

On this news, the price of Erasca stock fell $2.34 per share, nearly 11%, to close at $19.15 per share on April 27, 2026. The complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that (1) ERAS-0015's preclinical data was based on improper comparisons to RevMed and placed Erasca at risk of violating patent and trade secret protections; and (2) based on the foregoing, Defendants lacked a reasonable basis for their positive statements related to ERAS-0015.

Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented. Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America —the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors , and a $475 million settlement in In re Merrill Lynch . For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes. If you have any questions about this Notice, your rights, or your interests, please contact: CONTACT: Pamela A...